{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477171011
| IUPAC_name = (''RS'')-4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
| image = oxyphenbutazone.svg
| width = 250px
| chirality = [[Racemic mixture]]
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|oxyphenbutazone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_US_comment = Withdrawn
| legal_UK = Withdrawn
| legal_AU = Withdrawn
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 129-20-4
| ATC_prefix = M01
| ATC_suffix = AA03
| ATC_supplemental  = {{ATC|M02|AA04}} {{ATC|S01|BC02}}
| PubChem = 104811
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB03585
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 94610
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A7D84513GV
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08324
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 76258
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1228
<!--Chemical data-->
| C=19 | H=20 | N=2 | O=3
| molecular_weight = 324.379 g/mol
| smiles = O=C2N(c1ccc(O)cc1)N(C(=O)C2CCCC)c3ccccc3.O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H20N2O3.H2O/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15;/h4-8,10-13,17,22H,2-3,9H2,1H3;1H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CNDQSXOVEQXJOE-UHFFFAOYSA-N
}}

'''Oxyphenbutazone''' is a [[nonsteroidal anti-inflammatory drug]] (NSAID).<ref>{{Cite journal 
| last1 = Singh | first1 = N. 
| last2 = Jabeen | first2 = T. 
| last3 = Somvanshi | first3 = R. K. 
| last4 = Sharma | first4 = S. 
| last5 = Dey | first5 = S. 
| last6 = Singh | first6 = T. P. 
| doi = 10.1021/bi0483561 
| title = Phospholipase A2as a Target Protein for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Crystal Structure of the Complex Formed between Phospholipase A2and Oxyphenbutazone at 1.6 Å Resolution† 
| journal = Biochemistry 
| volume = 43 
| issue = 46 
| pages = 14577–14583 
| year = 2004 
| pmid = 15544328 
| pmc = 
}}</ref> It is a [[metabolite]] of [[phenylbutazone]].<ref>{{Cite journal 
| last1 = Matthews | first1 = N. S. 
| last2 = Peck | first2 = K. E. 
| last3 = Taylor | first3 = T. S. 
| last4 = Mealey | first4 = K. L. 
| title = Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys 
| journal = American journal of veterinary research 
| volume = 62 
| issue = 5 
| pages = 673–675 
| year = 2001 
| pmid = 11341383
}}</ref>

It was withdrawn from markets worldwide in mid-1980s due to bone marrow suppression and [[Stevens–Johnson syndrome]].<ref name=Fung-2001>{{cite journal|last=Fung|first=M.|author2=Thornton, A. |author3=Mybeck, K. |author4=Wu, J. H.-h. |author5=Hornbuckle, K. |author6= Muniz, E. |title=Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999|journal=Therapeutic Innovation & Regulatory Science|date=1 January 2001|volume=35|issue=1|pages=293–317|doi=10.1177/009286150103500134}}</ref><ref>{{cite journal |last1=Biron |first1=P |title= Withdrawal of oxyphenbutazone: what about phenylbutazone? |journal= Canadian Medical Association Journal |date= 15 May 1986 |volume= 134 |issue=10 |pages=1119–20 |pmid= 3697857 |pmc= 1491052}}</ref>

==References==
{{reflist}}

{{Anti-inflammatory and antirheumatic products}}
{{Topical products for joint and muscular pain}}

[[Category:Nonsteroidal anti-inflammatory drugs]]
[[Category:Pyrazolidindiones]]
[[Category:Phenols]]
[[Category:Withdrawn drugs]]


{{musculoskeletal-drug-stub}}